BioSpace News Archive

Tiziana Life Sciences Ltd. today announced a publication in the preeminent1 journal, Proceedings of the National Academy of Sciences (PNAS), that illustrates the immunological basis of the mechanism of action (MoA) for intranasal foralumab.

Zimmer Biomet Holdings, Inc. today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2023.

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences.

Alterity Therapeutics today announced the first participant in Italy has been dosed in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

Minerva Neurosciences, Inc. today reported business updates and financial results for the fourth quarter and year ended December 31, 2022.

Biogen Inc . (NASDAQ: BIIB) today announced that the Board of Directors has elected Caroline Dorsa as Chair of the Board of Directors, effective immediately following the Company’s 2023 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to take place on June 14, 2023.

Genprex, Inc. today announced the Company’s participation in the following upcoming investor and industry conferences to be held in March 2023.

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced that Cory R. Nicholas, Ph.D., Neurona’s chief executive officer, will provide a corporate update at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15 at 2:00 pm ET.

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2022.

Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2022 after the market close on Wednesday, March 15, 2023.